 |
 |
More careful study of the Lees paper in the BMJ, reviewed in today's post of Current Science Reviews, revealed a) 782 participants were assigned in 3 groups, and only 520 were divided between levodopa alone and levodopa plus selegiline, the rest getting bromocriptine alone, so the numbers are consistent with the companion commentary; b) causes of death in the first 2 groups were indeed tabulated, but not in great detail. 44 out of 249 subjects on levodopa alone, and 76 out of 271 subjects on levodopa plus selegiline, died during the 5 to 6 years of the trial. The biggest difference was 26 of the second group deaths assigned to "Parkinson's Disease" compared to 7 in the first group. Deaths from "cerebrovascular disease" were 11 in the second group vs. 2 in the first, but in "other cardiovascular disease" the result was reversed, 1 vs. 7. Sorry for the confusion, haste makes waste. I suggest adding this note to your file of monthly Reviews. Cheers, Joe J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks CA 91403